Gofd hydrogel for the treatment of radioactive skin damage and preparation and application thereof

Abstract

The application discloses a GOFD hydrogel which can be used for treating radioactive skin injury and preparation and application thereof. The GOFD hydrogel is obtained by self-assembly of polydopamine modified graphene oxide, basic fibroblast growth factor FGF2, single-stranded DNA Y1, single-stranded DNA Y2, single-stranded DNA Y3, single-stranded DNA L4 and single-stranded DNA L5. The GOFD hydrogel not only can play a role of mechanical support and filling a wound, but also has obvious cell migration promoting activity and antioxidant activity, can effectively promote the formation of blood vessels in a damaged part and healing of the damaged part, and has a wide market prospect in preparation of a radiation protection agent and a medicine for treating radioactive skin injury.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of hydrogels, and particularly relates to a GOFD hydrogel for treating radioactive skin damage and preparation and application thereof. BACKGROUND

[0002] Radiotherapy is a very common and effective treatment in modern medicine. Radiotherapy on cancer sites is one of the mainstream tumor intervention measures to inhibit tumors. However, during radiotherapy, due to the high radiation equivalent dose of the adjacent normal tissue irradiated exceeding its own tolerance, it is inevitable to cause undesirable radioactive damage. Radioactive skin damage is one of the common but debilitating side effects, and 95% of cancer patients will have different degrees of radioactive skin damage after radiotherapy. And with the accumulation of irradiation times and doses, the clinical and pathological manifestations of radioactive dermatitis are initially erythema, dry peeling, and in severe cases, it develops into wet peeling, and even skin necrosis. These radiation-induced skin damage can lead to cross-infection-prone skin lesions, resulting in a decline in the quality of life of patients, and in severe cases, it can lead to interruption of tumor treatment. In irradiation radiotherapy, high-energy ionizing radiation X-rays are mainly used. X-rays can directly cause DNA damage and produce a large amount of active oxygen by reacting with water, and excessive active oxygen will further damage the epidermal basal layer cells, and the damage to the epidermal basal layer cells has a serious impact on the normal metabolism and regeneration function of the skin tissue. According to the damage mechanism of radioactive dermatitis, there is an urgent need for a free radical scavenger as an effective skin radiation protection agent to remove the excessive ROS produced by X-rays, thereby blocking the development of radioactive skin damage from the source, and accelerating the healing of the wounds that have already been caused.

[0003] The existing hydrogel dressing technology for treating radioactive skin damage wounds mainly has the following problems: first, the biocompatibility of the wound treatment hydrogel dressing is generally poor; second, most of the existing hydrogel dressings are mainly used to reduce infection and relieve local symptoms, lack of biological activity, and cannot effectively promote the healing of radioactive skin damage wounds at the molecular level; third, most of the existing hydrogels lack antibacterial and active oxygen resistance properties, and cannot well protect the wound. SUMMARY

[0004] In order to solve the above problems, the application provides a GOFD hydrogel for treating radioactive skin damage and preparation and application thereof.

[0005] To achieve the above purpose, the application provides the following technical scheme:

[0006] The first aspect of the present application provides a GOFD hydrogel for treating radioactive skin damage, wherein the GOFD hydrogel is self-assembled by polydopamine modified graphene oxide, basic fibroblast growth factor FGF2, single-stranded DNA Y1, single-stranded DNA Y2, single-stranded DNA Y3, single-stranded DNA L4 and single-stranded DNA L5.

[0007] The nucleotide sequence of the single-stranded DNA Y1 is 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3',

[0008] The nucleotide sequence of the single-stranded DNA Y2 is 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3',

[0009] The nucleotide sequence of the single-stranded DNA Y3 is 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3',

[0010] The nucleotide sequence of the single-stranded DNA L4 is 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3', and the nucleotide sequence of the single-stranded DNA L5 is 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

[0011] The second aspect of the present application provides a preparation method of the above-mentioned GOFD hydrogel, comprising the following steps:

[0012] S1: graphene oxide is added into Tris buffer solution, ultrasonic treatment is carried out at room temperature for 2 hours, then dopamine is added, stirring is carried out at room temperature for 48 hours, centrifugation is carried out, the obtained precipitate is washed with distilled water and 95vol% ethanol respectively, and then drying is carried out at 40 DEG C, to obtain polydopamine modified graphene oxide;

[0013] S2: the single-stranded DNA Y1, the single-stranded DNA Y2 and the single-stranded DNA Y3 are mixed in PBS buffer solution, 95 DEG C heat preservation is carried out for 2 minutes, and then cooling is carried out to 25 DEG C at a rate of 0.1 DEG C / 0.06 s, to obtain a Y monomer solution;

[0014] S3: the single-stranded DNA L4 and the single-stranded DNA L5 are mixed in PBS buffer solution, 95 DEG C heat preservation is carried out for 2 minutes, and then cooling is carried out to 25 DEG C at a rate of 0.1 DEG C / 0.06 s, to obtain an L monomer solution;

[0015] S4: mixing and incubating Y monomer solution and basic fibroblast growth factor FGF2 solution at 20-35 DEG C for 2 min to obtain product A; mixing and incubating L monomer solution and polydopamine modified graphene oxide solution at 20 DEG C for 2 min to obtain product B; stirring and mixing product A and product B at 20 DEG C for 1 min to obtain GOFD hydrogel for treating radioactive skin injury;

[0016] In step S1, the mass ratio of graphene oxide and dopamine is 1:1;

[0017] In step S2, the molar ratio of single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 is 1:1:1;

[0018] In step S3, the molar ratio of single-stranded DNA L4 and single-stranded DNA L5 is 1:1;

[0019] In step S4, the content of Y monomer in the GOFD hydrogel is 250-500 mu mol / L, the content of basic fibroblast growth factor FGF2 in the GOFD hydrogel is 0.5-1 ng / mu L, the content of L monomer in the GOFD hydrogel is 375-700 mu mol / L, and the content of polydopamine modified graphene oxide in the GOFD hydrogel is 0.05-0.15 mg / ml.

[0020] The third aspect of the application provides the application of the above-mentioned GOFD hydrogel, which is any one or more of the following:

[0021] 1) application in the preparation of a drug for promoting cell migration;

[0022] 2) application in the preparation of an antioxidant drug;

[0023] 3) application in the preparation of a drug for promoting angiogenesis;

[0024] 4) application in the preparation of a radio-protective agent;

[0025] 5) application in the preparation of a drug for treating radioactive skin injury.

[0026] The significant advantages of the application are:

[0027] a) the application first uses basic fibroblast growth factor FGF2 as a radioactive skin injury wound healing material, encapsulates basic fibroblast growth factor FGF2 and polydopamine modified graphene oxide into a physically cross-linked DNA hydrogel, develops a multifunctional DNA gel with strong shape adaptability, biodegradability, biocompatibility, antioxidant property and immunomodulatory property, and first treats radioactive skin injury through a DNA hydrogel, which has minimal cytotoxicity, non-immunogenicity and satisfactory biocompatibility.

[0028] b) The preparation process of the GOFD hydrogel of the present application is simple. The GOFD hydrogel loaded with basic fibroblast growth factor FGF2 and polydopamine modified graphene oxide has antioxidant capacity. When the DNA hydrogel is used for wound healing treatment, the excess reactive oxygen species at the wound can be effectively removed, thereby promoting the healing recovery of the wound.

[0029] c) The GOFD hydrogel of the present application has a sustained release effect on basic fibroblast growth factor FGF2, which can improve the characteristics of short half-life and poor stability of basic fibroblast growth factor FGF2 itself. Once the drug is used, the concentration of basic fibroblast growth factor FGF2 at the wound can be maintained for a long time to meet the conditions of continuous anti-inflammatory and promote wound healing, reduce the drug application cycle, and improve the treatment effect that can be achieved by once drug use.

[0030] d) The GOFD hydrogel of the present application can be self-degraded during the treatment process. The GOFD hydrogel has good biocompatibility. The physically cross-linked hydrogel itself is relatively soft and can adapt to various shapes and irregular depth of the wound, without causing further mechanical damage. It also provides a scaffold for the cells of the new tissue.

[0031] e) The present application constructs the hydrogel by Y monomers and L monomers. The method is relatively mature, the operation steps are simple, and the judgment result has high reliability. BRIEF DESCRIPTION OF DRAWINGS

[0032] Figure 1 : Preparation flow chart of GOFD hydrogel.

[0033] Figure 2 : TEM diagram of polydopamine modified graphene oxide.

[0034] Figure 3 : Actual picture of GOFD hydrogel.

[0035] Figure 4 : Cell migration activity of GOFD hydrogel.

[0036] Figure 5 : In vitro antioxidant activity of GOFD hydrogel.

[0037] Figure 6 : Intracellular antioxidant activity of GOFD hydrogel.

[0038] Figure 7 : In vitro angiogenesis promoting ability of GOFD hydrogel.

[0039] Figure 8 : Radioprotective ability diagram of GOFD hydrogel.

[0040] Figure 9 Figure. Experimental results of GOFD hydrogel in animal model radiation protection and injury healing. DETAILED DESCRIPTION

[0041] In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be described clearly and completely below with reference to the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by a person of ordinary skill in the art without creative labor fall within the protection scope of the present application. Therefore, the following detailed description of the embodiments of the present application provided in the drawings is not intended to limit the scope of the claimed present application, but only represents selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by a person of ordinary skill in the art without creative labor fall within the protection scope of the present application.

[0042] The nucleotide sequences of single-stranded DNA involved in the following examples are as follows:

[0043] Y1: 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3',

[0044] Y2: 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3',

[0045] Y3: 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3',

[0046] L4: 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3',

[0047] L5: 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

[0048] Example 1

[0049] The present embodiment provides a preparation method of GOFD hydrogel, and the steps are as follows:

[0050] S1: Preparation of polydopamine modified graphene oxide: 30 mg of graphene oxide was added to Tris buffer solution (10 mM, pH 8.5) and ultrasonicated in a water bath at room temperature for 2 h. Then 30 mg of dopamine was added and stirred at room temperature for 48 h. The obtained precipitate was centrifuged at 8000 rpm for 10 min, washed with distilled water and 95 vol% ethanol for 3 times, and dried in an oven at 40℃ for 12 h to obtain polydopamine modified graphene oxide (GO@PDA).

[0051] S2: Preparation of Y monomer: Y1 was prepared into a solution with a concentration of 250 μM using 1 × PBS buffer solution (pH 7.2), Y2 was prepared into a solution with a concentration of 250 μM using 1 × PBS buffer solution (pH 7.2), and Y3 was prepared into a solution with a concentration of 250 μM using 1 × PBS buffer solution (pH 7.2). The Y1 solution, Y2 solution and Y3 solution were mixed in a volume ratio of 1:1:1, incubated at 95℃ for 2 min, and then cooled to 25℃ at a rate of 0.1℃ / 0.06s to obtain a Y monomer solution with a concentration of 160 μM.

[0052] S3: Preparation of L monomer: L4 was prepared into a solution with a concentration of 375 μM using 1 × PBS buffer solution (pH 7.2), and L5 was prepared into a solution with a concentration of 375 μM using 1 × PBS buffer solution (pH 7.2). The L4 solution and L5 solution were mixed in a volume ratio of 1:1, incubated at 95℃ for 1 min, and then cooled to 25℃ at a rate of 0.1℃ / 0.06s to obtain an L monomer solution with a concentration of 240 μM.

[0053] S4: Preparation of hydrogel: 24 μL of the Y monomer solution with a concentration of 160 μM and 1 μL of a basic fibroblast growth factor FGF2 solution with a concentration of 1 ng / μL were mixed and incubated at 20℃ for 2 min to obtain product A; 24 μL of the L monomer solution with a concentration of 240 μM and 1 μL of a polydopamine modified graphene oxide solution with a concentration of 0.1 mg / mL were mixed and incubated at 20℃ for 2 min to obtain product B; the obtained product A and product B were mixed and stirred at 20℃ for 1 min until the mixture was gel-like to obtain a GOFD hydrogel.

[0054] Figure 1 Figure 1 is a schematic diagram of the preparation process of the GOFD hydrogel. Figure 2 Figure 2 is a TEM image of the polydopamine modified graphene oxide. As shown in the figure, the polydopamine modified graphene oxide has a typical transparent and wrinkled sheet structure, and the particle size is about 1 μm. Figure 3 Figure 3 is a physical image of the GOFD hydrogel.

[0055] Comparative Example:

[0056] The present comparative example provides a preparation method of a DNA hydrogel, and the steps are as follows:

[0057] S1: Preparation of Y monomer: Y1 was prepared into a solution with a concentration of 250 mM using 1x PBS buffer (pH 7.2), Y2 was prepared into a solution with a concentration of 250 mM using 1x PBS buffer (pH 7.2), and Y3 was prepared into a solution with a concentration of 250 mM using 1x PBS buffer (pH 7.2); the Y1 solution, the Y2 solution and the Y3 solution were mixed in a volume ratio of 1:1:1, incubated at 95°C for 2 min, and then cooled to 25°C at a rate of 0.1°C / 0.06 s to obtain a Y monomer solution with a concentration of 160 mM.

[0058] S2: Preparation of L monomer: L4 was prepared into a solution with a concentration of 375 mM using 1x PBS buffer (pH 7.2), and L5 was prepared into a solution with a concentration of 375 mM using 1x PBS buffer (pH 7.2); the L4 solution and the L5 solution were mixed in a volume ratio of 1:1, incubated at 95°C for 1 min, and then cooled to 25°C at a rate of 0.1°C / 0.06 s to obtain an L monomer solution with a concentration of 240 mM.

[0059] S3: Preparation of hydrogel: the Y monomer solution with a concentration of 160 mM and the L monomer solution with a concentration of 240 mM were mixed in a volume ratio of 1:1 at 20°C, and the mixture was stirred for 1-2 min until it became gel-like to obtain a DNA hydrogel.

[0060] Example 2:

[0061] Logarithmic growth phase HacaT cells were inoculated in a 6-well plate at a density of 5x10 5 cells per well, and when the cells in the 6-well plate reached 90% coverage, a sterile micropipette tip was used to gently scratch the cells vertically to produce vertical scratches, and then the cells were co-cultured with DMEM medium containing GOFD hydrogel, and DMEM medium without GOFD hydrogel was used as a blank control group. After co-culturing for 0 h, 24 h and 48 h, the cell scratch area was observed and photographed using an optical microscope, and the cell migration rate was calculated using Image J software. The 24 h cell migration rate = (scratch area at 0 h-scratch area at 24 h) / scratch area at 0 h. The 48 h cell migration rate = (scratch area at 0 h-scratch area at 48 h) / scratch area at 0 h. As shown in Figure 4 the table, the 24 h cell migration rate of the GOFD hydrogel treatment group was 1.48 times that of the blank control group, and the 48 h cell migration rate of the GOFD hydrogel treatment group was 1.41 times that of the blank control group. This shows that the GOFD hydrogel has good ability to promote cell migration.

[0062] Example 3:

[0063] ABTS ethanol solution of 2.84 g / L and potassium persulfate solution of 0.664 g / L were mixed in a ratio of 1:1 by volume, then placed in the dark for 15 h to obtain ABTS mother liquor, which was diluted with anhydrous ethanol to an absorbance of 0.7±0.02 at 734 nm before the experiment to make it into ABTS working solution, while GOFD hydrogel and commonly used drugs SOD on the market were also prepared. 100 μL of ABTS working solution was mixed with 100 μL of ultrapure water to serve as a control group; 100 μL of ABTS working solution was mixed with 100 μL of GOFD hydrogel and 100 μL of SOD sample solution, respectively, to serve as experimental groups. After incubation in the dark at room temperature for 10 minutes, the absorption spectrum curves of all groups in the range of 500-900 nm were measured by ultraviolet-visible spectrophotometer. Quantitative experiments were carried out using a 96-well plate, with 3 replicate wells in each group. The results are shown in Figure 5 As can be seen from the figure, GOFD hydrogel has good antioxidant activity in vitro.

[0064] Example 4:

[0065] HaCaT cells were seeded in a confocal dish at a density of 1.5×10 5 cells / dish, and cultured for 24 hours; the cells were incubated with 100 μL of PBS (Control), DNA hydrogel, GOFD hydrogel, GO@PDA, and 1.5 mL of DMEM medium, respectively, for 12 hours. After incubation, the cells were washed with PBS for 3 times, then 1 mL of DMEM medium containing DCFH-DA probe (5 μL) was added to each dish (the probe mother liquor concentration was 1 mg / mL), and the cells were incubated in a 37°C incubator for 20 minutes; the cells were washed with PBS for 3 times to remove the excess probe that did not enter the cells; then the cells were exposed to X-rays with a dose of 6 Gy at a dose rate of 1 Gy / min for 6 minutes; finally, CLSM was used to take pictures (using an objective lens of 60x oil lens and a laser type of 488 nm laser). The results are shown in Figure 6 As can be seen from the figure, DNA hydrogel, GOFD hydrogel, and GO@PDA can all well protect cells from radiation damage, and GOFD hydrogel has the best effect.

[0066] Example 5:

[0067] Pre-cool 24-well plates and 1 mL syringe tips in -20 °C refrigerator, and Matrigel matrix gel is also dissolved in ice made by ice maker in advance; use pre-cooled syringe tips to suck 250 μL of Matrigel matrix gel into 24-well plates, pay attention to avoid air bubbles and ensure that the gel covers the bottom of the hole (operate on the ice box); place the 24-well plates in a 37 °C incubator for 30 minutes to make the matrix gel solidify evenly; during the waiting time for the matrix gel to solidify, digest the HUVEC cells, resuspend the cells with 1 mL of DMEM medium after centrifugation, and then add 100 μL of PBS (Control), DNA hydrogel, GOFD hydrogel, GO@PDA to the cells, respectively; add 250 μL of cell suspension to each well, and the cell density is 5 × 10 4 6 / well, pay attention to avoid air bubbles, and the syringe tip should not touch the matrix gel; after 24 hours of culture in the cell incubator, take photos to observe tube formation under a microscope. The results are shown in Figure 7 Fig. 6, the number of tubes, grids, nodes and tube length of the GOFD hydrogel group are better than those of other groups, indicating that the GOFD hydrogel group has good in vitro ability to promote angiogenesis.

[0068] Example 6:

[0069] HaCaT cells in the logarithmic growth phase were digested, centrifuged, and counted using a cell counter, and then seeded in a 6-well plate at a density of 2 × 10 3 6 / well, shake the cells and then place them in a cell incubator for 24 hours; discard the original culture medium and replace it with 1.5 mL of DMEM medium containing 100 μL of GOFD hydrogel, mark it and then continue to culture in the cell incubator for 24 hours; discard the culture medium containing the hydrogel solution and wash the cells with PBS once, then add 1 mL of fresh DMEM complete medium to each well, and then expose the cells to X-rays with a total dose of 6 Gy and a dose rate of 1 Gy / min; after irradiation, the cells continue to be cultured in the cell incubator, and the cell condition is observed during the culture process and fresh culture medium is replaced in time according to the growth of the cells. About 5-7 days later, obvious visible cell clonal groups are observed in the 6-well plate, at which time the culture is terminated; discard the original culture medium and wash the cells with PBS once, then fix and stain the cells with 0.25% crystal violet staining solution (500 μL per well) for 30 minutes, then discard the staining solution and immerse the 6-well plate in running water for 2-3 times, then invert it on the desktop and let it dry naturally; invert the 6-well plate on the flat plate of the gel imager, and use the gel imaging system to scan the clonal plate and collect the image. The results are shown in Figure 8 Fig. 7, the survival rate of the cells under the protection of the GOFD hydrogel is higher, indicating that the GOFD hydrogel has excellent radio-protective ability.

[0070] Example 7:

[0071] Control group, GOFD gel group BALB / c mice after anesthesia (0.4% sodium pentobarbital intraperitoneal, according to 1 ml / 100g body weight dose of mice, 3% sodium pentobarbital, 1 mL / kg), the back exposed to the set dose rate irradiation area of 1.0 cm x 1.0 cm skin, the total dose of 50 Gy per mouse, and mark the irradiation site, remove the hair. Subsequently GOFD gel group wound with GOFD gel hydrogel completely covered, the control group wound not covered with GOFD gel hydrogel. All surgical procedures were performed in a sterile room. After 4d, 9d, 16d, 25d, the control group, hydrogel treatment group wound healing were observed, each group of wound were photographed and measured wound size, wound area was calculated. As shown in Table 1, compared with the control group, the GOFD gel group radiotherapy dermatitis appeared delay, skin damage to recovery time is relatively short, hair recovery and hair growth is relatively fast. Prove that GOFD hydrogel in animal models have good radiation protection performance and damage healing ability. Figure 9

[0072] The above only for the preferred embodiments of the present application, any changes and modifications made in accordance with the scope of the present application patent application, should be included in the scope of the present application.​

Claims

1. A GOFD hydrogel for the treatment of radiation-induced skin damage, characterized in that: The GOFD hydrogel is self-assembled by polydopamine modified graphene oxide, basic fibroblast growth factor FGF2, single-stranded DNA Y1, single-stranded DNA Y2, single-stranded DNA Y3, single-stranded DNA L4 and single-stranded DNA L5. The nucleotide sequence of the single-stranded DNA Y1 is 5'-ACTTGACTTAACTCATAGTTATCATGCACGCGATCGATCGTTAATGATATTACGTGATATCGA-3', The nucleotide sequence of the single-stranded DNA Y2 is 5'-ACTTGACTTAACTTCGATATCACGTAATATCATTAACGACCGATCATTCCGTGAGCGTTAACG-3', The nucleotide sequence of the single-stranded DNA Y3 is 5'-ACTTGACTTAACTCGTTAACGCTCACGGAATGATCGGTATCGATCGCGTGCATGATAACTATG-3', The nucleotide sequence of the single-stranded DNA L4 is 5'-AGTTAAGTCAAGTTGAGGTAGACTTAACTATCT-3', The nucleotide sequence of the single-stranded DNA L5 is 5'-AGTTAAGTCAAGTAGATAGTTAAGTCTACCTCA-3'.

2. The method of claim 1, wherein the GOFD hydrogel is prepared by: The method comprises the following steps: S1: graphene oxide is added to Tris buffer solution, ultrasonic treatment in a water bath at room temperature for 2 hours, then dopamine is added, stirring at room temperature for 48 hours, centrifugation, the obtained precipitate is washed with distilled water and 95%vol ethanol respectively, and then dried at 40°C to obtain polydopamine modified graphene oxide; S2: single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 are mixed in PBS buffer solution, incubated at 95°C for 2 minutes, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain a Y monomer solution; S3: single-stranded DNA L4 and single-stranded DNA L5 are mixed in PBS buffer solution, incubated at 95°C for 2 minutes, and then cooled to 25°C at a rate of 0.1°C / 0.06s to obtain an L monomer solution; S4: the Y monomer solution and the basic fibroblast growth factor FGF2 solution are mixed and incubated at 20-35°C for 2 minutes to obtain product A; The L monomer solution and the polydopamine modified graphene oxide solution are mixed and incubated at 20°C for 2 minutes to obtain product B; The product A and the product B are stirred and mixed at 20°C for 1 minute to obtain the GOFD hydrogel for treating radioactive skin damage.

3. The method of claim 2, wherein: In step S1, the mass ratio of graphene oxide to dopamine is 1:

1.

4. The method of claim 2, wherein: In step S2, the molar ratio of single-stranded DNA Y1, single-stranded DNA Y2 and single-stranded DNA Y3 is 1:1:

1.

5. The method of claim 2, wherein: In step S3, the molar ratio of single-stranded DNA L4 to single-stranded DNA L5 is 1:

1.

6. The method of claim 2, wherein: The content of Y monomers in the GOFD hydrogel is 250-500 μmol / L, the content of basic fibroblast growth factor FGF2 in the GOFD hydrogel is 0.5-1 ng / μL, the content of L monomers in the GOFD hydrogel is 375-700 μmol / L, and the content of polydopamine modified graphene oxide in the GOFD hydrogel is 0.05-0.15 mg / ml in step S4.

7. Use of a GOFD hydrogel according to claim 1, characterized in that: The application is any one or more of the following: 1) application in the preparation of antioxidant drugs; 2) application in the preparation of radiation protection agents; 3) application in the preparation of drugs for treating radiation-induced skin damage.

Images